259 related articles for article (PubMed ID: 38044747)
21. Identification of an immune-based mRNA-lncRNA signature for overall survival in cervical squamous cell carcinoma.
Mao Y; Chen R; Xia M; Guo P; Zeng F; Huang J; He M
Future Oncol; 2021 Jun; 17(18):2365-2380. PubMed ID: 33724869
[TBL] [Abstract][Full Text] [Related]
22. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
Zuo S; Wei M; Wang S; Dong J; Wei J
Front Immunol; 2020; 11():1218. PubMed ID: 32714316
[No Abstract] [Full Text] [Related]
23. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
24. A novel DNA damage repair-related gene signature predicting survival, immune infiltration and drug sensitivity in cervical cancer based on single cell sequencing.
Xiang X; Kang J; Jiang J; Zhang Y; Zhang Y; Li L; Peng X
Front Immunol; 2023; 14():1198391. PubMed ID: 37449209
[TBL] [Abstract][Full Text] [Related]
25. Identification of
Zhao S; Yu M
DNA Cell Biol; 2020 Feb; 39(2):255-272. PubMed ID: 31977248
[TBL] [Abstract][Full Text] [Related]
26. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
27. Functional enrichment analysis of LYSET and identification of related hub gene signatures as novel biomarkers to predict prognosis and immune infiltration status of clear cell renal cell carcinoma.
Chen Y; He J; Jin T; Zhang Y; Ou Y
J Cancer Res Clin Oncol; 2023 Dec; 149(18):16905-16929. PubMed ID: 37740762
[TBL] [Abstract][Full Text] [Related]
28. Decreased expression of CLCA2 and the correlating with immune infiltrates in patients with cervical squamous cell carcinoma: A bioinformatics analysis.
Yang X; Cao JL; Yang FN; Li XF; Tao LM; Wang F
Taiwan J Obstet Gynecol; 2021 May; 60(3):480-486. PubMed ID: 33966732
[TBL] [Abstract][Full Text] [Related]
29. Developing a prognosis and chemotherapy evaluating model for colon adenocarcinoma based on mitotic catastrophe-related genes.
Liu Y; Zhao Y; Zhang S; Rong S; He S; Hua L; Wang X; Chen H
Sci Rep; 2024 Jan; 14(1):1655. PubMed ID: 38238555
[TBL] [Abstract][Full Text] [Related]
30. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
31. Multiple programmed cell death patterns and immune landscapes in bladder cancer: Evidence based on machine learning and multi-cohorts.
Li Z; Li Y; Liu L; Zhang C; Li X
Environ Toxicol; 2024 Mar; 39(3):1780-1801. PubMed ID: 38064272
[TBL] [Abstract][Full Text] [Related]
32. Identification and characterization of aging/senescence-induced genes in osteosarcoma and predicting clinical prognosis.
Lv Y; Wu L; Jian H; Zhang C; Lou Y; Kang Y; Hou M; Li Z; Li X; Sun B; Zhou H
Front Immunol; 2022; 13():997765. PubMed ID: 36275664
[TBL] [Abstract][Full Text] [Related]
33. Construction of prognosis model of pyroptosis gene and characterization of tumor microenvironment infiltration in cervical cancer.
Zhang M; Wu P
Medicine (Baltimore); 2022 Nov; 101(46):e31599. PubMed ID: 36401372
[TBL] [Abstract][Full Text] [Related]
34. Construction of a four-mRNA prognostic signature with its ceRNA network in CESC.
Li L; Guo Q; Lan G; Liu F; Wang W; Lv X
Sci Rep; 2022 Jun; 12(1):10691. PubMed ID: 35739227
[TBL] [Abstract][Full Text] [Related]
35. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
36. Gene signatures, immune infiltration, and drug sensitivity based on a comprehensive analysis of m6a RNA methylation regulators in cervical cancer.
Lu X; Li R; Ying Y; Zhang W; Wang W
J Transl Med; 2022 Sep; 20(1):385. PubMed ID: 36058934
[TBL] [Abstract][Full Text] [Related]
37. Characterization of tumor microenvironment and programmed death-related genes to identify molecular subtypes and drug resistance in pancreatic cancer.
Yu L; He R; Cui Y
Front Pharmacol; 2023; 14():1146280. PubMed ID: 37007021
[No Abstract] [Full Text] [Related]
38. Tumor purity as a prognosis and immunotherapy relevant feature in cervical cancer.
Deng Y; Song Z; Huang L; Guo Z; Tong B; Sun M; Zhao J; Zhang H; Zhang Z; Li G
Aging (Albany NY); 2021 Nov; 13(22):24768-24785. PubMed ID: 34844217
[TBL] [Abstract][Full Text] [Related]
39. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
40. Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer.
Shen C; Chai W; Han J; Zhang Z; Liu X; Yang S; Wang Y; Wang D; Wan F; Fan Z; Hu H
Front Immunol; 2023; 14():1213947. PubMed ID: 37965307
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
